ライフサイエンスコーパス: idiopathic Parkinson's disease

1 underscoring a pathophysiology distinct from idiopathic Parkinson's disease.

2 emerging earlier and more frequently than in idiopathic Parkinson's disease.

3 s, 25 healthy controls, and 25 patients with idiopathic Parkinson's disease.

4 PINK1-mitophagy is a contributing factor to idiopathic Parkinson's disease.

5 ciated with GBA mutations, and modestly with idiopathic Parkinson's disease.

6 2) are the most common cause of familial and idiopathic Parkinson's disease.

7 ld improve postural control in patients with idiopathic Parkinson's disease.

8 nsation for dopamine loss in experimental or idiopathic Parkinson's disease.

9 ofile similar to that previously reported in idiopathic Parkinson's disease.

10 t the causative role of paraquat exposure in idiopathic Parkinson's disease.

11 pamine neurons is characteristic of advanced idiopathic Parkinson's disease.

12 ) has an increasing role in the treatment of idiopathic Parkinson's disease.

13 tation, and had typical clinical findings of idiopathic Parkinson's disease.

14 veries and to discuss their relationships to idiopathic Parkinson's disease.

15 tern of nigrostriatal dysfunction typical of idiopathic Parkinson's disease.

16 substitution at codon 2019 (Gly2019 ser), in idiopathic Parkinson's disease.

17 physiology of resting and postural tremor in idiopathic Parkinson's disease.

18 ut the Lewy body pathology characteristic of idiopathic Parkinson's disease.

19 e and a clinical syndrome closely resembling idiopathic Parkinson's disease.

20 diseases, including Alzheimer's disease and idiopathic Parkinson's disease.

21 ly indistinguishable from most patients with idiopathic Parkinson's disease.

22 lower than those reported for patients with idiopathic Parkinson's disease.

23 changes reminiscent of those which occur in idiopathic Parkinson's disease.

24 he specific mutation (A53T) in a 40 cases of idiopathic Parkinson's disease, 3 cases of multisystem a

25 Twenty-one patients with idiopathic Parkinson's disease (46-76 years old, 11 male

26 pared to controls persisted in patients with idiopathic Parkinson's disease (after exclusion of all G

27 ganglia was investigated in 25 patients with idiopathic Parkinson's disease and 14 matched healthy co

28 A total of 17 patients with idiopathic Parkinson's disease and 16 age- and sex-match

29 20 patients with idiopathic Parkinson's disease and 21 healthy participan

30 e non-demented subjects with newly diagnosed idiopathic Parkinson's disease and 37 healthy matched co

31 movement have been studied in patients with idiopathic Parkinson's disease and age-matched healthy i

32 sess variant frequencies in individuals with idiopathic Parkinson's disease and controls, matched for

33 idal disorders: idiopathic torsion dystonia, idiopathic Parkinson's disease and Huntington's disease,

34 predictive potential to discriminate between idiopathic Parkinson's disease and Parkinson's disease l

35 solated from control subjects, patients with idiopathic Parkinson's disease and Parkinson's disease p

36 al mitophagy, a process with strong links to idiopathic Parkinson's disease, and demonstrates that ph

37 resynaptic dopamine storage in patients with idiopathic Parkinson's disease as a function of the cate

38 Eligible patients were aged 25-75 years, had idiopathic Parkinson's disease as measured by Queen Squa

39 ing network structure in 37 individuals with idiopathic Parkinson's disease, both ON and OFF dopamine

40 en described with a phenotype much closer to idiopathic Parkinson's disease, but it does not appear t

41 how that fibroblasts from five patients with idiopathic Parkinson's disease can be efficiently reprog

42 Idiopathic Parkinson's disease can present with symptoms

43 tation and clinical features consistent with idiopathic Parkinson's disease, carriers of the autosoma

44 neuron-specific gene expression patterns in idiopathic Parkinson's disease cases.

45 d DJ-1 to be an abundant protein in control, idiopathic Parkinson's disease, cases with clinical and

46 fered significantly from that of control and idiopathic Parkinson's disease cells.

47 (r -0.66, 95% CI -0.88 to -0.20; p=0.0099), idiopathic Parkinson's disease cohort 1 (r -0.66, -0.84

48 1 (r -0.66, -0.84 to -0.36; p=0.00031), and idiopathic Parkinson's disease cohort 2 (r -0.71, -0.84

49 e also recruited one cohort of patients with idiopathic Parkinson's disease (cohort 1) from Movement

50 gid syndromes of less than 5 years duration: idiopathic Parkinson's disease corticobasal degeneration

51 nts (56 +/- 7 years) suffering from moderate idiopathic Parkinson's disease (disease duration 10 +/-

52 Differentiating idiopathic Parkinson's disease from atypical parkinsonia

53 Differentiation of idiopathic Parkinson's disease from MSA is important bec

54 esponses to clonidine clearly differentiated idiopathic Parkinson's disease from MSA-C and MSA-P.

55 ne/growth hormone (GH) testing distinguishes idiopathic Parkinson's disease from MSA.

56 ed 86 deceased older Catholic clergy without idiopathic Parkinson's disease from the Religious Order

57 Image-based classification for idiopathic Parkinson's disease had 84% sensitivity, 97%

58 se association between cigarette smoking and idiopathic Parkinson's disease has been reported in seve

59 The etiology of idiopathic Parkinson's disease (idPD) remains enigmatic

60 e, 26 female) cases were diagnosed as having idiopathic Parkinson's disease (IPD) and 70 (42 male, 28

61 lsy (PSP), multiple system atrophy (MSA) and idiopathic Parkinson's disease (IPD) can be clinically i

62 Idiopathic Parkinson's disease (iPD) is believed to have

63 The etiology of idiopathic Parkinson's disease (iPD) is multifactorial,

64 The accurate diagnosis of idiopathic Parkinson's disease (IPD) is not only importa

65 Idiopathic Parkinson's disease (iPD) is the second most

66 s) rich in alpha-synuclein are a hallmark of idiopathic Parkinson's disease (iPD) pathology.

67 uptake (P = 0.0008) compared with a group of idiopathic Parkinson's disease (IPD) patients who had ba

68 y the role of neuronal complex 1 activity in idiopathic Parkinson's disease (IPD), expression of mito

69 Of these men, 92 subsequently developed idiopathic Parkinson's disease (IPD).

70 l mechanisms underlying neurodegeneration in idiopathic Parkinson's disease (iPD).

71 essive neurodegenerative disorder similar to idiopathic Parkinson's disease (IPD).

72 alue as biomarkers of disease progression in idiopathic Parkinson's disease (iPD).

73 ive losses of cardiac sympathetic neurons in idiopathic Parkinson's disease (IPD).

74 Postural instability (PI) is common in idiopathic Parkinson's disease (IPD).

75 opulation of 217 subjects, many of which had idiopathic Parkinson's disease (IPD).

76 rlier in the cancer trajectory but rarely in Idiopathic Parkinson's Disease(IPD), Progressive Supranu

77 Interestingly, in idiopathic Parkinson's disease, iron homeostasis is alte

78 Idiopathic Parkinson's disease is a common neurodegenera

79 Idiopathic Parkinson's disease is characterized by a pro

80 al Parkinson's disease, but its relevance to idiopathic Parkinson's disease is unclear.

81 y syndrome, peduncular hallucinosis, treated idiopathic Parkinson's disease, Lewy body dementia witho

82 pars compacta of controls and subjects with idiopathic Parkinson's disease matched for age and postm

83 sed serum GH concentrations in patients with idiopathic Parkinson's disease (median increase 8.98 [IQ

84 tient astrocytes showed CD44 overexpression, idiopathic Parkinson's disease microglia revealed a pro-

85 Moreover, nigral idiopathic Parkinson's disease microglia were more amoeb

86 ingle-nuclei RNA sequencing dataset from the idiopathic Parkinson's disease midbrain, which highlight

87 TH levels, which was exclusively present in idiopathic Parkinson's disease midbrains.

88 re to differentiate individual patients with idiopathic Parkinson's disease, multiple system atrophy,

89 We also discovered a reduction in idiopathic Parkinson's disease oligodendrocyte numbers w

90 Multiple system atrophy and idiopathic Parkinson's disease patient groups had minima

91 nscriptomes of post-mortem midbrain from six idiopathic Parkinson's disease patients and five age-/se

92 duals harbouring mutations in PRKN/PINK1 and idiopathic Parkinson's disease patients remain elusive.

93 , while no such association was observed for idiopathic Parkinson's disease patients.

94 nographically, median follow-up: 1.6 years), idiopathic Parkinson's disease (PD) (n=909, median follo

95 The genetic epidemiology of late-onset idiopathic Parkinson's disease (PD) and 'parkin-proven'

96 peripheral lymphocytes of 43 newly diagnosed idiopathic Parkinson's disease (PD) cases and 62 age- an

97 ny compelling basis for a heritable basis of idiopathic Parkinson's disease (PD) has focused attentio

98 Idiopathic Parkinson's disease (PD) is an age dependent,

99 Idiopathic Parkinson's disease (PD) is an age-dependent,

100 loss of nigral dopaminergic (DA) neurons in idiopathic Parkinson's disease (PD) is believed to resul

101 Idiopathic Parkinson's disease (PD) is often accompanied

102 on of nigrostriatal dopamine (DA) neurons in idiopathic Parkinson's disease (PD) is still unknown.

103 The pathogenic mechanisms underlying idiopathic Parkinson's disease (PD) remain enigmatic.

104 or many years, visual hallucinations (VH) in idiopathic Parkinson's disease (PD) were thought to be a

105 atients with parkinsonian disorders: 86 with idiopathic Parkinson's disease (PD), 30 with progressive

106 We also analyzed six cases of idiopathic Parkinson's disease (PD), one case of familia

107 In idiopathic Parkinson's disease (PD), pathologic alphaSyn

108 sm, and through analysis of a subcohort with idiopathic Parkinson's disease (PD), we have demonstrate

109 orts the Braak hypothesis in the etiology of idiopathic Parkinson's disease (PD).

110 site of origin for a-synuclein pathology in idiopathic Parkinson's disease (PD).

111 py is important in supporting a diagnosis of idiopathic Parkinson's disease (PD).

112 en thought to have a role in the etiology of idiopathic Parkinson's disease (PD).

113 eus (STN) accompany movement difficulties in idiopathic Parkinson's disease (PD).

114 iseases such as Alzheimer's disease (AD) and idiopathic Parkinson's disease (PD).

115 ns, Lewy bodies, which are characteristic of idiopathic Parkinson's disease (PD).

116 The concept of 'idiopathic' Parkinson's disease (PD) as a single entity

117 thermore, astrocytes and microglia presented idiopathic Parkinson's disease-specific cell proliferati

118 uscles in the forearm of seven patients with idiopathic Parkinson's disease, studied with and without

119 Patients with idiopathic Parkinson's disease suffer not only from clas

120 tals, we randomly assigned 299 patients with idiopathic Parkinson's disease to undergo either pallida

121 ver study, 19 patients with mild-to-moderate idiopathic Parkinson's disease underwent functional magn

122 However, Lewy body pathology typical of idiopathic Parkinson's disease was found at autopsy in t

123 The GH response to clonidine in idiopathic Parkinson's disease was significantly differe

124 esting and postural tremors of patients with idiopathic Parkinson's disease were monitored using tran

125 Twenty-one patients with advanced idiopathic Parkinson's disease were studied.

126 l as significant reductions in patients with idiopathic Parkinson's disease, which correlates with th

127 eterozygous PRKN/PINK1 mutations compared to idiopathic Parkinson's disease, which is in line with pr

128 -75 years, had been diagnosed with bilateral idiopathic Parkinson's disease with motor symptoms for m

129 age between 22 and 75 years, a diagnosis of idiopathic Parkinson's disease with over 5 years of moto

130 To this end, 20 patients with idiopathic Parkinson's disease with subthalamic nucleus

131 d the effects of clonidine on 14 people with idiopathic Parkinson's disease (without autonomic defici

132 nucleus (STN DBS) improves motor symptoms in idiopathic Parkinson's disease, yet the mechanism of act